Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer is looking to use AI in a Singapore initiative to shorten the drug discovery process. Read more at straitstimes.com.

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer Inc.’s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug ...

While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative acquisition, and it projects Seagen to contribute $10 billion in sales by 2030.

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...